Dyadic International (DYAI) Cash from Financing Activities (2018 - 2025)
Dyadic International (DYAI) posted Cash from Financing Activities of -$1.0 for Q4 2025, down 100.0% sequentially from $4.9 million in Q3 2025, and down 100.0% YoY from $24251.0 in Q4 2024.
Dyadic International (DYAI) Cash from Financing Activities (2018 - 2025) Analysis & Trends
Dyadic International has reported Cash from Financing Activities for 7 years, with the latest figure at -$1.0 in Q4 2025.
- Quarterly Cash from Financing Activities fell 100.0% year-over-year to -$1.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.0 million (down 15.11% YoY) and the FY2025 annual result came in at $5.0 million, down 15.11% from the prior year.
- Cash from Financing Activities slipped to -$1.0 in Q4 2025 per DYAI's latest filing, from $4.9 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $115.8 million in Q1 2021 and troughed at -$114.8 million in Q2 2021.
- A 4-year average of $1.0 million and a median of $91925.0 in 2022 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 66071.43% in 2021, down 206070.01% in 2021.
- Over 4 years, Cash from Financing Activities stood at $244500.0 in 2021, then sank by 42.13% to $141500.0 in 2022, then sank by 82.86% to $24251.0 in 2024, then tumbled by 100.0% to -$1.0 in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$1.0, $4.9 million, and $24249.0 for Q4 2025, Q3 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.00 |
| Dec 31, 2025 | -1.00 |
| Sep 30, 2025 | 4.94 Mn |
| Sep 30, 2025 | 4.94 Mn |
| Mar 31, 2025 | 24,249.00 |
| Mar 31, 2025 | 24,249.00 |
| Dec 31, 2024 | 24,251.00 |
| Dec 31, 2024 | 24,251.00 |
| Mar 31, 2024 | 5.82 Mn |
| Mar 31, 2024 | 5.82 Mn |
| Dec 31, 2022 | 141,500.00 |
| Dec 31, 2022 | 141,500.00 |
| Sep 30, 2022 | 359,741.00 |
| Sep 30, 2022 | 359,741.00 |
| Mar 31, 2022 | 42,350.00 |
| Mar 31, 2022 | 42,350.00 |
| Dec 31, 2021 | 244,500.00 |
| Dec 31, 2021 | 244,500.00 |
| Sep 30, 2021 | -590.00 |
| Sep 30, 2021 | -590.00 |